Animalcare Group Reports Robust First-Half 2025 Performance with Strategic Growth Initiatives

Animalcare ( (GB:ANCR) ) has provided an update.

Animalcare Group plc reported a strong first-half performance for 2025, with double-digit revenue and profit growth driven by the acquisition and integration of Randlab. Revenues increased by 18.5% to £43.8m, and underlying EBITDA grew by 39.5% to £9.2m. The company continues to invest in innovation and strategic opportunities, including a strategic equity stake in InVetro, to expand its presence in the Asia-Pacific region. The Group’s financial health supports ongoing M&A and R&D activities, with a focus on developing its product pipeline through partnerships and acquisitions, such as the VHH NGF antibody programme.

The most recent analyst rating on (GB:ANCR) stock is a Hold with a £284.00 price target. To see the full list of analyst forecasts on Animalcare stock, see the GB:ANCR Stock Forecast page.

Spark’s Take on GB:ANCR Stock

According to Spark, TipRanks’ AI Analyst, GB:ANCR is a Neutral.

Animalcare’s overall stock score reflects strong corporate events and financial stability, offset by bearish technical indicators and high valuation concerns. Strategic expansions and acquisitions bolster future growth potential, but technical analysis suggests caution in the short term.

To see Spark’s full report on GB:ANCR stock, click here.

More about Animalcare

Animalcare Group plc is a UK AIM-listed international veterinary sales and marketing organisation. It operates in seven European countries, as well as Australia, New Zealand, and the UAE, exporting to approximately 40 countries globally. The Group focuses on bringing new and innovative products to market through its development pipeline, partnerships, and acquisitions.

Average Trading Volume: 69,393

Technical Sentiment Signal: Buy

Current Market Cap: £172.5M

Find detailed analytics on ANCR stock on TipRanks’ Stock Analysis page.